Dandelion Diagnostics develops point-of-care diagnostic tools utilizing nanoscale photonic sensors and artificial intelligence to interpret disease fingerprints. This technology enables rapid, lower-cost diagnosis for complex and previously difficult-to-detect diseases. The company focuses on significantly reducing the time required for accurate disease identification.
Funding
Funding not disclosed
Founders
Product
Problem
Diagnosing complex diseases often involves lengthy, multi-stage processes that can take years, delaying critical treatment initiation. Current diagnostic methods may lack the sensitivity or specificity required for early detection of challenging conditions.
Solution
Dandelion Diagnostics is developing an AI-powered biosensor platform designed for rapid, point-of-care disease diagnosis. The technology leverages nanoscale photonic sensors to generate unique "disease fingerprints" by detecting subtle biological markers. These fingerprints are then analyzed by proprietary AI algorithms to identify and quantify disease states with increased speed and accuracy. This approach aims to significantly reduce the time from sample to diagnosis for complex and previously difficult-to-diagnose conditions, enabling faster clinical decision-making.
Target Audience
The primary target audience includes clinical laboratories, hospitals, and research institutions seeking advanced diagnostic tools for complex diseases.
Features
- Nanoscale photonic sensors for high-sensitivity detection of biological analytes.
- AI-driven analysis of sensor data to generate unique disease-specific fingerprints.
- Platform designed for point-of-care application, enabling rapid results.
- Focus on diagnosing complex diseases with improved speed and cost-effectiveness.
- Potential for application in early detection of challenging medical conditions.